v212
Vaccineexperimental
Clinical trial activity
8 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
4
Phase 3
3
Phase 4
0
Earliest trial started Nov 1, 2007 (NCT00535236)
Timeline
Indications
Mechanism of action
- Human herpesvirus 3Immunity, active
Human herpesvirus 3 immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- v212
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02180295 | Phase 3 | Jul 1, 2014 | Merck |
| NCT01527383 | Phase 2 | Feb 1, 2012 | Merck |
| NCT01460719 | Phase 1 | Jan 24, 2012 | Merck |
| NCT01254630 | Phase 3 | Jun 24, 2011 | Merck |
| NCT01229267 | Phase 3 | Nov 1, 2010 | Merck |
| NCT00886613 | Phase 1 | Mar 1, 2009 | Merck |
| NCT00696709 | Phase 1 | Dec 1, 2008 | Merck |
| NCT00535236 | Phase 1 | Nov 1, 2007 | Merck |
Showing 8 of 8 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Merck | For profit | 8 | 8 | 3 | 2007 |
1 organizations
Page 1 / 1